1 Genetic Insights into Cardiac Conduction Disorders from

2 Genome-Wide Association Studies

- 3 Running title: GWAS Uncovers Genetic Links to Cardiac Conduction Disorders
- 4
- 5 Bingxun Li, PhD^{1,2*}, Hongxuan Xu, PhD^{1,2*} and Lin Wu, MD^{1,2,3#}
- ¹ Department of Cardiology, Peking University First Hospital, Beijing, China.
- ² State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University
- ³Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of
- 9 Cardiovascular Research, Southwest Medical University, Luzhou, China.
- 10 #Corresponding author: Lin Wu; E-mail: <u>wuepgroup@126.com</u>; address: NO.8
- 11 Xishiku Street, Department of Cardiology, Peking University First Hospital, Beijing,
- 12 China.
- 13 *These authors contributed equally to this study.
- 14
- 15 Number of total words: 4,465
- 16 Number of words in the abstract: 197
- 17 Number of references: 40
- 18

19 ABSTRACT

20 **BACKGROUND**: Substantial data support a heritable basis for cardiac conduction 21 disorders (CCDs), but the genetic determinants and molecular mechanisms of these 22 arrhythmias are poorly understood, therefore, we sought to identify genetic loci 23 associated with CCDs. METHODS: We performed meta-analyses of genome-wide 24 association studies to identify genetic loci for atrioventricular block (AVB), left 25 bundle branch block (LBBB), and right bundle branch block (RBBB) from public 26 data from the UK Biobank and FinnGen consortium. We assessed evidence 27 supporting the potential causal effects of candidate genes by analyzing relations 28 associated variants and cardiac gene expression, between performing 29 transcriptome-wide analyses, and ECG-wide phenome-wide associations for each 30 indexed SNP. RESULTS: Analysis comprised over 700,000 individuals for each trait. 31 We identified 10, 4 and 0 significant loci for AVB (PLEKHA3, TTN, FNDC3B, 32 SENP2, SCN10A, RRH, PPARGC1A, PKD2L2, NKX2-5 and TBX20), LBBB (PPARGC1A, HAND1, 33 TBX5, and ADAMTS5) and RBBB, respectively. 34 Transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of SCN10A and AVB. Phenome-wide associations 35 identified traits with both cardiovascular and non- cardiovascular traits with indexed 36 37 SNPs. **CONCLUSIONS**: Our analysis highlight gene regions associated with channel 38 function, cardiac development, sarcomere function and energy modulation as 39 important potential effectors of CCDs susceptibility.

40 Key words: Genome-Wide Association Studies, cardiac conduction disorders,

41 meta-analysis

42

43 The cardiac conduction system is crucial for propagating electrical signals that 44 coordinate cardiac contractions to maintain effective blood circulation. Disturbances 45 in this system, termed cardiac conduction disorders (CCDs), can disrupt heart depolarization and even result in bradycardia. Common manifestations of CCDs 46 47 include sick sinus syndrome (SSS), atrioventricular block (AVB), left bundle branch block (LBBB), and right bundle branch block (RBBB). While significant progress has 48 49 been made in understanding the molecular mechanisms driving CCDs, current treatments for CCDs is limited and primarily rely on implantable devices such as 50 pacemakers¹. As a result, further research is needed to enhance our understanding and 51 52 facilitate the development of pharmacological or genetic therapies².

Although some CCDs can arise secondary to conditions such as ischemia, toxins, 53 54 or infections¹, genetic factors also play a significant role in their development, with studies indicating that CCDs and risk for pacemaker insertion cluster within 55 families^{3,4}. Some researchers also suggested to include genetic testing as part of the 56 diagnostic workup in AVB patients⁵. In 2021, Thorolfsdottir et al. conducted a 57 genome-wide association study (GWAS) that identified several novel genetic variants 58 associated with SSS, underscoring a strong genetic basis⁶. However, GWAS studies 59 on other major CCDs such as AVB, LBBB, or RBBB, are not yet fully explored. To 60 address this gap, we performed a meta-analysis of GWAS data on AVB, LBBB, and 61 62 RBBB to gain further insight into the pathogenesis of these disorders.

63 Methods

64 Study samples and meta-analysis

65 The study was reported according to STrengthening the REporting of Genetic Association Studies (STREGA) guideline⁷. Figure 1 depicts the study design. We 66 included individuals with the phenotypes of interest from UK Biobank⁸ and the 67 FinnGen consortium release 11⁹. Details of each cohort as well as download link of 68 69 GWAS summary statistics are provided in Supplemental Table1. Because those 70 GWAS data are from two independent cohorts, there was no risk sample overlap. We then conducted meta-analysis of included GWAS analyses using a fixed-effects 71 inverse variance weighted approach implemented in METAL¹⁰, utilizing the default 72 method that incorporates p-values and the direction of effect, weighted by sample size. 73 74 To address potential population stratification bias, we applied genomic control to all 75 input files. SNPs with allele frequency < 0.5% were excluded from our analysis¹¹. 76 Because the output file of METAL doesn't include BETA and SE (standard error),

which are essential for further analysis, we calculated the above parameters from the following formulations¹²:

79

$$SE = \sqrt{\frac{1}{2 \times EAF \times (1 - EAF) \times (N + Z^2)}}$$

80

81 where EAF is effect allele frequency, N is sample size, and Z is Z score.

82 Identification of independent locus and novel genes

83 We used the 1000 Genomes Project phase 3 European (EUR) sample for linkage

 $BETA = Z \times SE$

disequilibrium (LD) estimation via the plinkbinr (version 0.0.0.9) and ieugwasr (version 1.0.2) packages in R (version 4.1.1). Independent locus were defined using a strict standard (clump window = 1Mb, $r^2 \Box = \Box 0.001$ and p-value $< 5 \times 10^{-8}$). Novel locus were defined as variants more than 500 kb from previously reported ones. We identified the gene closest to the indexed SNP according to Ensembl within a 500 KB region. CADD (Combined Annotation Dependent Depletion) scaled score for each SNP was looked up in the CADD v1.7 website (https://cadd.gs.washington.edu/snv)¹³.

91 Transcriptome-wide association study

We applied transcriptome-wide association study (TWAS) to identify significant 92 expression-trait associations using expression imputation from genetic data or 93 summary statistics with FUSION software¹⁴. This software trains predictive models of 94 the genetic component of a functional or molecular phenotype and predicts and tests 95 that component for association with disease using GWAS summary statistics. 96 FUSION software was used to generate SNP weight sets from BLUP, BSLMM, 97 98 LASSO, Elastic Net, and top SNPs utilizing genotype and expression data unless 99 BLUP/BSLMM was eliminated owing to sample size or convergence issues. Our goal was to identify associations between the phenotypes of interest and a functional 100 101 phenotype measured only in reference data; for this analysis, we selected the GTEx version 8 heart left ventricle data¹⁵. A false discovery rate (FDR) < 0.05 was 102 considered significant. In addition, we conducted colocalization analysis for results 103 with p-value < 0.05 using the coloc package (version 5.1.1)¹⁶. Colocalization was 104 assessed via posterior probability for hypothesis 4 (PP.H₄), with PP.H₄ > 80% 105 indicating significant shared causal variants. We also conduct the joint/conditional 106 107 tests for further verification.

108 LD score regression

We used LD Score regression (LDSC)¹⁷ to estimate genetic correlations between 109 AVB, LBBB, and RBBB with 9 cardiovascular traits, including Brugada syndrome¹⁸, 110 heart failure (HF)¹⁹, coronary heart disease (CAD)²⁰, atrial fibrillation (AF)²¹, SSS⁶, 111 QRS duration (from Pan-UKBB GWAS), PR interval²², systolic blood pressure 112 $(SBP)^{23}$ and heart rate $(HR)^{24}$ utilizing the ldscr package (version 0.1.0) in R. 113 European LD scores were obtained from the 1000 Genomes Project Phase 3 data for 114 HapMap2 SNPs. A p-value below 0.0019 (0.05/9/3) was considered significant for 115 LDSC. Additionally, we also analyzed the genetic associations of each clumped SNP 116 117 against those risk factors.

118 Phenome-wide Mendelian randomization

119 To perform Phenome-wide Mendelian randomization (PheWAS) analysis, we 120 queried the GWAS atlas database (https://atlas.ctglab.nl)²⁵, which contains 4756 121 GWAS summary statistics for each indexed SNP. P-values $< 7.51 \square \times \square 10^{-7}$ 122 (0.05/4756/14) was considered as significant. For those PheWAS results fulfilled the 123 adjusted p-value, we also conducted colocalization analysis for further verification.

124 ECG-wide association analyses.

Clumped variants of LBBB and AVB GWAS data were looked up in ECGenetics
 (http://www.ecgenetics.org)²⁶ to explore their effect on R-R adjusted three-lead
 exercise electrocardiogram (ECG) morphology. The GWAS for ECG morphology

128 consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank 129 across the complete cycle of cardiac conduction by plotting 500 association signals of 130 each datapoint as $-\log_{10}(p\text{-values})$ along the time axis of one heartbeat. This analysis 131 aims to assess the impact of clumped LBBB and AVB variants on ECG morphology, 132 leveraging extensive phenotyping data from the UK Biobank. By visualizing the 133 association signals as $-\log_{10}(p\text{-values})$, the study seeks to elucidate the relationship

134 between genetic variants and cardiac conduction throughout a complete heartbeat.

135 Results

Meta-analysis results and gene annotation revealed novel genes for AVB andLBBB

138 We conducted meta-analyses of genome-wide association results for AVB, 139 LBBB, and RBBB using data from the UK Biobank and FinnGen consortium. After 140 quality control, we analyzed 19,629,603 SNPs for AVB, 19,630,647 SNPs for LBBB, 141 and 19,631,437 SNPs for RBBB, respectively. Manhattan plots for each trait are 142 shown in **Figure 2**, while quantile-quantile (QQ) plots and lambda values 143 (Supplementary Figure 1) indicated no evidence of inflation. We identified 298 SNPs for AVB, 10 for LBBB, and 1 for RBBB reached GW-significance (i.e., 144 p-value $\square < \square 5 \square \times \square 10^{-8}$). After LD clumping, 10 SNPs remained for AVB (2 novel 145 146 SNPs), 4 SNPs for LBBB (2 novel SNPs), and none for RBBB. Details of clumped 147 SNPs are listed in **Table 1**. We identified 10 loci for AVB and 4 loci for LBBB, 148 respectively, in which 2 novel loci for both AVB (rs56065557, rs7433306) and LBBB 149 (rs1472095, rs9636578) were identified.

We then mapped potential genes according to distances on each chromosome for
indexed SNPs. We identified *PLEKHA3*, *TTN*, *FNDC3B*, *SENP2*, *SCN10A*, *RRH*, *PPARGC1A*, *PKD2L2*, *NKX2-5*, *TBX20* as potential genes for AVB indexed SNPs.
For LBBB indexed SNPs, the potential genes included *PPARGC1A*, *HAND1*, *TBX5*,
and *ADAMTS5*.

TWAS analysis indicated SCN10A as potential modulator for AVB

156 In the single-tissue internal validation using FUSION, of the 5,886 genes included in our genotype data showing significant cis-genetic expression in whole 157 blood according to the GTEx dataset, 10 and 2 genes revealed significant association 158 159 signals in the TWAS with a FDR p-value less than 0.05 for AVB and LBBB, 160 respectively, as detailed in **Supplementary Table S2** and illustrated in 161 Supplementary Figure 2. No significant results were obtained for RBBB GWAS. 162 After colocalization analysis, there were only 4 genes with PP.H4 > 0.80. In 163 subsequent joint/conditional tests, we found that after conditioning on 164 ENSG00000185313.6 (SCN10A) in the AVB GWAS data on chromosom 3, in which 165 this locus goes from being genome-wide significant to non-significant after 166 conditioning on the predicted expression of ENSG00000185313.6 (SCN10A), as 167 shown in **Supplementary Figure 3.** The other 3 genes didn't have any locus with 168 strong enough signals to visualize due to weak effects or low statistical power.

Genetic correlation estimates showed associations between CCDs with
 cardiovascular traits

171

155

Estimates of the genetic correlation between AVB, LBBB, RBBB and 9 risk

factors are reported in **Table 2**, in which only results with p-value < 0.0019 are listed. 172 173 We found that CAD and AF were closely correlated with all 3 CCDs, and HF was 174 correlated with AVB and LBBB. Supplementary Figure 4 showed genetic 175 associations of clumped locus s against 9 cardiovascular traits. Notably, while AVB 176 and PR interval exhibited a strong correlation, we did not identify a significant 177 correlation between QRS duration and LBBB/RBBB. This is likely due to the fact that 178 PR interval and AVB are both focused on the atrioventricular node, a specific 179 conduction pathway, whereas QRS duration reflects a broader range of electrical 180 processes within the ventricles. These processes may not always align genetically 181 with the more localized conduction abnormalities in LBBB and RBBB. The 182 difference in complexity and specificity of these traits explains why a strong genetic 183 correlation was found in the former pair but not in the latter. Additionally, we found that BrS and RBBB didn't share as much strong genetic correlation as expected. This 184 might indicate that although initially reported as a RBBB-like ECG change²⁷, BrS and 185 186 RBBB are distinct diseases with different genetic background.

187 ECG-wide associations

188 The influence of indexed SNPs on ECG morphology is shown in 189 Supplementary Figure 5. We showed the ECG morphology phenotype plots as well 190 as the heatmaps for the indexed SNPs. The plots showed that the genetic ECG signature of 191 AVB clumped SNPs mainly affected the PR-segment morphology on the ECG, and LBBB 192 indexed SNPs mainly affected the QRS wave morphology.

193 PheWAS analysis

194 The results of PheWAS were present in **Supplementary Table 5**. We found that 195 apart from AF and some common ECG traits such as PR interval, HR, the indexed 196 SNPs in our analysis were also to be highly associated with other non-cardiac traits, 197 estimated glomerular filtration rate, impedance measures, body such as 198 anthropometric traits, etc. Because the GWAS data of ECG traits from Genevieve Wojcik et al²⁸ were not from individuals of European ancestry, we excluded those 199 200 from our results and conducted colocalization analysis. After colocalization analysis, 201 we identified that some traits with high colocalization evidence (PP.H4 > 0.80) with 202 indexed SNPs, and the virtualization of those results were present in **Supplementary** 203 **Figure 6 - 11**.

204 **Discussion**

205 In this meta-analysis of GWAS for 3 clinically important CCDs using 2 independent cohorts, we identified 10 and 2 genome-wide disease susceptibility loci 206 207 for AVB and LBBB, respectively, including 2 novel locus were identified for each 208 GWAS. Our findings primarily highlighted genes involved in ion channel function, 209 sarcomere function, cardiac development and energy modulation, supporting and extending previous findings suggesting an genetic basis of CCDs and underscore the 210 complex genetic architecture underlying these disorders³⁻⁶. Additionally, they suggest 211 212 potential pathways for future research and therapeutic targeting.

213 Most susceptibility locus are associated with genes that affect cardiac ion 214 channels, such as *SCN10A*, *TBX20* and *TBX5*. Variations in *SCN10A* have been 215 identified to influence cardiac conduction and PR interval²⁹. TWAS analysis also suggested *SCN10A* as an important regulator for AVB. The T-box proteins are also
 essential for cardiac conduction system morphogenesis and activation or repression of
 key regulatory genes³⁰. These genes primarily impact the cardiac conduction system,
 potentially leading to conduction delays.

220 We also observed susceptibility locus for both AVB and LBBB that mapped to 221 *PPARGC1A* (also known as *PGC-1* α), an important mitochondrial energy metabolism 222 factor, suggesting that PPARGC1A may be an important modulator for cardiac 223 conduction. PPARGC1A is involved in the regulation of oxidative phosphorylation and mitochondrial biogenesis, processes critical for maintaining cellular energy 224 homeostasis, and is closely associated with cardiovascular diseases³¹. Disruption of 225 mitochondrial function can lead to altered ion channel expression and disrupted Ca² 226 homeostasis, which in turn increases susceptibility to arrhythmias in both atrial³² and 227 ventricular tissues³³ in mice with *PPARGC1A* deficiency. 228

229 Our results further implicate the cardiac sarcomere for AVB and LBBB. We 230 identified a susceptibility locus for AVB at PLEKHA3, located just downstream of 231 TTN. TTN encodes the large cardiac structural protein titin, which is essential for the 232 assembly and function of vertebrate striated muscles. By providing connections at the 233 level of individual microfilaments, titin helps maintain the delicate balance of forces between the two halves of the sarcomere. Variants in TTN are among the most 234 common inheritable risk factors for dilated cardiomyopathy³⁴ and have been 235 associated with early-onset AF³⁵. A recent research also identified TTN as an 236 237 important susceptibility locus paroxysmal supraventricular arrhythmia related to accessory pathways³⁶. 238

239 We also found some genes associated with cardiac development. The Small 240 Ubiquitin-like Modifier (SUMO) modification, implicated in various cellular 241 processes including protein trafficking, transcriptional regulation, protein stability, 242 cell death, and survival, is important to maintain physiological function. SUMOylation of several ion channels such as SCN5A to affect conduction³⁷. We 243 244 found SENP2, a key member of the SENPs family that regulates SUMOylation, in AVB susceptibility locus. The downstream target of SENP2 including NKX2-5³⁸, 245 246 another identified gene in AVB GWAS data, which functions in heart formation and 247 development. Mutations in this gene cause atrial septal defect with atrioventricular 248 conduction defect, and also tetralogy of Fallot, which are both heart malformation diseases³⁹. Another gene with potential influence on cardiac development is HAND1 249 250 as one of LBBB susceptibility locus. HAND1 is a key transcription factor involved in 251 early cardiogenesis. It is one of two closely related family members known as the 252 HAND proteins, which are asymmetrically expressed in the developing ventricular 253 chambers and play an essential role in cardiac morphogenesis. Acting in a 254 complementary manner, these proteins are crucial for the formation of the right 255 ventricle and the aortic arch arteries, implicating them as significant mediators of 256 congenital heart disease⁴⁰.

We also observed some genes, such as RRH, FNDC3B, and ADAMTS5, that have not been extensively studied in the context of cardiovascular function. Additionally, our PheWAS analysis revealed that some indexed SNPs were closely

associated with non-cardiac traits, including estimated glomerular filtration rate
(eGFR). These findings suggest a broader role for these genes and SNPs beyond
traditional cardiovascular implications, highlighting the need for further investigation
into their functions.

264 Limitations

We recognize several limitations in our analysis. Firstly, the genetic data primarily derives from individuals of European ancestry, which may restrict the applicability of our findings to other ethnic groups. Secondly, despite a total sample size exceeding 700,000, we did not retain SNPs in the RBBB GWAS data after clumping. Further studies are necessary to address this gap.

270 Conclusion

In this meta-analysis of GWAS including 2 independent cohorts and over 700,000 European individuals, we identified 10 and 2 previously reported genome-wide associations with AVB and LBBB, respectively, and 2 novel associations for each GWAS. Our findings primarily implicate genes involved in ion channel function, cardiac development, sarcomere function and energy modulation as important potential effectors of risk for AVB and LBBB.

277 Data availability

All the data used were acquired from publicly available dataset according to the PubMed ID or links provided in **Stable 1**. No restricted dataset was used in this study. The summary statistics didn't contain any personal information. For code supporting this manuscript, please refer to <u>https://github.com/bingxunli/block</u>.

282 Authors' contributions

BX Li and HX Xu (first author): Conceptualization, Methodology, Software, Investigation, Formal Analysis, Writing and Original Draft; Y Chen and YY Lin: Data Curation, Writing and Original Draft; L Wu (Corresponding Author): Writing, Review and Editing, Funding acquisition. All authors have reviewed the manuscript and approved its submission in current version.

288 Ethics approval

289 Not applicable

290 Consent to participate

- 291 Not applicable
- 292 **Consent for publication**
- 293 Not applicable

294 Acknowledgments

We would like to extend our deepest appreciation to the providers of open data and all the individuals who participated in the studies.

297 Funding

This work is funded by National Natural Science Foundation of China (Project approval number: 82370312).

300 References

301 1 Kusumoto, F. M. et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and

- 302 Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of
- 303 the American College of Cardiology/American Heart Association Task Force on
- 304 Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* 140,
- 305 e382-e482, doi:10.1161/cir.00000000000628 (2019).
- 2 Li, T., Marashly, Q., Kim, J. A., Li, N. & Chelu, M. G. Cardiac conduction diseases:
- 307 understanding the molecular mechanisms to uncover targets for future treatments.
- 308 Expert opinion on therapeutic targets **28**, 385-400,
- 309 doi:10.1080/14728222.2024.2351501 (2024).
- 310 3 Kaess, B. M. *et al.* Familial Clustering of Cardiac Conduction Defects and Pacemaker
 311 Insertion. *Circulation. Arrhythmia and electrophysiology* **12**, e007150,
 312 doi:10.1161/circep.119.007150 (2019).
- 313 4 Dyssekilde, J. R. *et al.* Familial risk of atrioventricular block in first-degree relatives.

314 *Heart* **108**, 1194-1199, doi:10.1136/heartjnl-2021-320411 %J Heart (2022).

- 315 5 Resdal Dyssekilde, J. *et al.* Diagnostic Yield of Genetic Testing in Young Patients With
- 316 Atrioventricular Block of Unknown Cause. Journal of the American Heart Association
- 317 **11**, e025643, doi:10.1161/jaha.121.025643 (2022).
- 318 6 Thorolfsdottir, R. B. *et al.* Genetic insight into sick sinus syndrome. *European heart*319 *journal* 42, 1959-1971, doi:10.1093/eurheartj/ehaa1108 (2021).
- 320 7 Little, J. et al. STrengthening the REporting of Genetic Association Studies (STREGA):
- an extension of the STROBE statement. *PLoS medicine* 6, e22,
 doi:10.1371/journal.pmed.1000022 (2009).
- 323 8 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

324 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).

- 325 9 Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
- 326 population. *Nature* **613**, 508-518, doi:10.1038/s41586-022-05473-8 (2023).
- 327 10 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of 328 genomewide association scans. *Bioinformatics (Oxford, England)* **26**, 2190-2191,
- 329 doi:10.1093/bioinformatics/btq340 (2010).
- 330 11 Rasooly, D. et al. Genome-wide association analysis and Mendelian randomization
- 331 proteomics identify drug targets for heart failure. *Nature communications* 14, 3826,
- doi:10.1038/s41467-023-39253-3 (2023).
- Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts
 complex trait gene targets. *Nature genetics* 48, 481-487, doi:10.1038/ng.3538 (2016).
- 335 13 Schubach, M., Maass, T., Nazaretyan, L., Röner, S. & Kircher, M. CADD v1.7: using
- 336 protein language models, regulatory CNNs and other nucleotide-level scores to
- improve genome-wide variant predictions. *Nucleic acids research* **52**, D1143-d1154,
- 338 doi:10.1093/nar/gkad989 (2024).
- Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
 studies. *Nature genetics* 48, 245-252, doi:10.1038/ng.3506 (2016).
- 341 15 The GTEx Consortium atlas of genetic regulatory effects across human tissues.
 342 *Science (New York, N.Y.)* 369, 1318-1330, doi:10.1126/science.aaz1776 (2020).
- 343 16 Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic
- 344 association studies using summary statistics. *PLoS genetics* **10**, e1004383,
- 345 doi:10.1371/journal.pgen.1004383 (2014).

9

- Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
 polygenicity in genome-wide association studies. *Nature genetics* 47, 291-295,
 doi:10.1038/ng.3211 (2015).
- 349 18 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk
- loci and highlight a new mechanism of sodium channel regulation in disease
 susceptibility. *Nature genetics* 54, 232-239, doi:10.1038/s41588-021-01007-6 (2022).
- 352 19 Shah, S. et al. Genome-wide association and Mendelian randomisation analysis
- 353 provide insights into the pathogenesis of heart failure. *Nature communications* **11**, 163,
- doi:10.1038/s41467-019-13690-5 (2020).
- Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nature genetics* **54**,
- 357 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).
- Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
 fibrillation biology. *Nature genetics* 50, 1234-1239, doi:10.1038/s41588-018-0171-3
 (2018).
- 361 22 Ntalla, I. *et al.* Multi-ancestry GWAS of the electrocardiographic PR interval identifies
 362 202 loci underlying cardiac conduction. *Nature communications* 11, 2542,
 363 doi:10.1038/s41467-020-15706-x (2020).
- 364 23 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
 365 associated with blood pressure traits. *Nature genetics* 50, 1412-1425,
 366 doi:10.1038/s41588-018-0205-x (2018).
- 367 24 van de Vegte, Y. J. et al. Genetic insights into resting heart rate and its role in

- 368 cardiovascular disease. *Nature communications* **14**, 4646,
- 369 doi:10.1038/s41467-023-39521-2 (2023).
- Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in
 complex traits. *Nature genetics* 51, 1339-1348, doi:10.1038/s41588-019-0481-0
- 372 (2019).
- 373 26 Verweij, N. *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* 11,
 374 229-238.e225, doi:10.1016/j.cels.2020.08.005 (2020).
- 375 27 Brugada, J., Brugada, R. & Brugada, P. Right bundle-branch block and ST-segment
- elevation in leads V1 through V3: a marker for sudden death in patients without
 demonstrable structural heart disease. *Circulation* 97, 457-460,
 doi:10.1161/01.cir.97.5.457 (1998).
- Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
 complex traits. *Nature* 570, 514-518, doi:10.1038/s41586-019-1310-4 (2019).
- 381 29 Chambers, J. C. *et al.* Genetic variation in SCN10A influences cardiac conduction.

382 *Nature genetics* **42**, 149-152, doi:10.1038/ng.516 (2010).

383 30 van Eif, V. W. W., Devalla, H. D., Boink, G. J. J. & Christoffels, V. M. Transcriptional

regulation of the cardiac conduction system. *Nature reviews. Cardiology* **15**, 617-630,

- 385 doi:10.1038/s41569-018-0031-y (2018).
- 386 31 Qian, L. *et al.* Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1)
- family in physiological and pathophysiological process and diseases. *Signal transduction and targeted therapy* 9, 50, doi:10.1038/s41392-024-01756-w (2024).
- 389 32 Chadda, K. R. et al. Gene and Protein Expression Profile of Selected Molecular

- 390 Targets Mediating Electrophysiological Function in Pgc-1α Deficient Murine Atria.
- 391 International journal of molecular sciences 19, doi:10.3390/ijms19113450 (2018).
- 392 33 Saadeh, K. et al. Molecular basis of ventricular arrhythmogenicity in a Pgc-1α deficient
- 393 murine model. *Molecular genetics and metabolism reports* 27, 100753,
- doi:10.1016/j.ymgmr.2021.100753 (2021).
- 395 34 Herman, D. S. *et al.* Truncations of titin causing dilated cardiomyopathy. *The New*396 *England journal of medicine* **366**, 619-628, doi:10.1056/NEJMoa1110186 (2012).
- 397 35 Choi, S. H. et al. Association Between Titin Loss-of-Function Variants and Early-Onset
- 398 Atrial Fibrillation. *Jama* **320**, 2354-2364, doi:10.1001/jama.2018.18179 (2018).
- 399 36 Weng, L. C. et al. Meta-Analysis of Genome-Wide Association Studies Reveals
- 400 Genetic Mechanisms of Supraventricular Arrhythmias. *Circulation. Genomic and* 401 *precision medicine* **17**, e004320, doi:10.1161/circgen.123.004320 (2024).
- 402 37 Yoon, J. Y. *et al.* SUMOylation of the cardiac sodium channel Na(V)1.5 modifies
 403 inward current and cardiac excitability. *Heart rhythm* 20, 1548-1557,
 404 doi:10.1016/j.hrthm.2023.07.067 (2023).
- 405 38 Wang, J., Zhang, H., Iyer, D., Feng, X. H. & Schwartz, R. J. Regulation of cardiac 406 specific nkx2.5 gene activity by small ubiquitin-like modifier. *The Journal of biological*
- 407 *chemistry* **283**, 23235-23243, doi:10.1074/jbc.M709748200 (2008).
- 408 39 Cao, C. *et al.* Nkx2.5: a crucial regulator of cardiac development, regeneration and
 409 diseases. *Frontiers in cardiovascular medicine* 10, 1270951,
 410 doi:10.3389/fcvm.2023.1270951 (2023).
- 411 40 Riley, P., Anson-Cartwright, L. & Cross, J. C. The Hand1 bHLH transcription factor is

412	essential for placentation and cardiac morphogenesis. Nature genetics 18, 271-275,
413	doi:10.1038/ng0398-271 (1998).
414	
415	
416	
417	
418	
419	
420	
421	
422	
423	
424	
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	Figure 1 Schematic diagram.
447	AVB, atrioventricular block; LBBB, left bundle branch block; RBBB, bundle branch
448	block; SNP, Single-Nucleotide Polymorphism; LD, linkage disequilibrium; LDSC,
449	LD score regression; PheWAS, phenome-wide association study; TWAS,
450	transcriptome-wide association study
451	
452	Figure 2. Manhattan plots showing GWAS meta-analysis of. A) AVB; B) LBBB; and
453	C) RBBB. Those plots shows the $-\log_{10}(p\text{-value})$ of association for each SNP from

- the GWAS meta-analysis plotted on the y-axis against genomic position on the x-axis.
- 455 The gray line corresponds to the genome-wide significance threshold $(5 \square \times \square 10^{-8})$.
- 456 Novel locus identified genes are highlighted in bold.

457

SNP	CHR	POS	EA	NEA	EAF	Ν	BETA	SE	p-value	nearest gene	CADD scaled score
AVB											
rs185591978	2	178488129	А	G	0.94	349625	-0.03	0.005	2.60×10^{-9}	PLEKHA3	1.44
rs13031826	2	178891875	А	Т	0.88	732669	-0.02	0.003	1.19×10^{-12}	TTN	4.28
rs10936712	3	172084486	Т	С	0.69	349625	-0.01	0.003	1.48×10^{-8}	FNDC3B	3.09
rs56065557	3	185636428	С	G	0.70	732669	-0.01	0.002	8.35×10 ⁻⁹	SENP2	1.44
rs7433306	3	38729148	С	G	0.57	732669	0.01	0.002	1.45×10^{-10}	SCN10A	0.29
rs199561133	4	110760807	Т	G	0.86	349625	-0.02	0.003	2.59×10^{-8}	RRH	0.57
rs2932971	4	23817261	Т	С	0.71	732669	0.01	0.002	1.89×10^{-10}	PPARGC1A	19.3
rs76734697	5	137897780	Т	G	0.81	732669	0.01	0.002	2.73×10 ⁻⁹	PKD2L2	3.15
rs6556061	5	173218944	А	Т	0.72	349625	-0.02	0.003	2.62×10^{-9}	NKX2-5	0.11
rs11764098	7	35466100	С	G	0.97	732669	-0.04	0.005	2.52×10^{-13}	TBX20	18.1
LBBB											
rs1472095	4	23816454	Т	С	0.71	727785	0.010	0.002	3.35×10 ⁻⁸	PPARGC1A	3.29
rs13185595	5	154492610	А	G	0.63	727785	-0.012	0.002	5.55×10^{-13}	HAND1	7.93
rs61931006	12	114414703	А	С	0.90	727785	0.018	0.003	4.10×10^{-11}	TBX5	2.64
rs9636578	21	27538384	Α	G	0.52	727785	-0.001	0.002	4.02×10^{-8}	ADAMTS5	2.94

Table 1. Locus reported for AVB and LBBB in the meta-analysis of UK Biobank and FinnGene GWAS datasets. Findings were identified using
fixed effects inverse-variance weighted meta-analysis. The chromosomal position is based on GRCh37/hg19 reference. Gene names are
italicized. Novel locus (i.e., distance > 500kB from previous locus) are shown in bold. CHR, chromosome; POS, base pair location; NEA,
non-effect allele; EA, effect allele; EAF, effect allele frequency; SE, standard error; CADD, Combined Annotation Dependent Depletion

Trait1	Trait2	r_{g}	SE	p-value
AVB	AF	0.46	0.07	6.86×10^{-10}
	CAD	0.30	0.05	$1.18 imes 10^{-9}$
	HF	0.48	0.08	5.17×10^{-10}
	SSS	0.32	0.07	$5.85 imes10^{-6}$
	PR	0.76	0.17	$5.41 imes 10^{-6}$
	HR	0.19	0.04	$1.98 imes 10^{-5}$
LBBB	AF	0.26	0.07	$1.19 imes 10^{-4}$
	CAD	0.40	0.06	7.59×10^{-12}
	HF	0.65	0.10	2.83×10^{-10}
	SBP	0.24	0.05	$7.16 imes 10^{-6}$
RBBB	AF	0.36	0.11	$1.10 imes 10^{-3}$
	CAD	0.51	0.09	$2.50 imes 10^{-8}$

463 Table 2. LDSC analysis results showing genetic correlations between CCDs and 464 related cardiovascular traits. Here only significant results were present. AVB, 465 atrioventricular block; LBBB, left bundle branch block; RBBB, right bundle branch 466 block; AF, atrial fibrillation; CAD, coronary heart disease; HF, heart failure; SSS, sick 467 sinus syndrome; SBP, systolic blood pressure; r_g , genetic correlation; SE, standard 468 error.

462





